• If you are wondering whether AbbVie at around US$227.73 is giving you enough value for the risk you are taking, the starting point is to understand how that price stacks up against different ways of estimating what the stock might be worth.
• Over the short term AbbVie has been relatively steady, with the stock up 0.2% over the past week and 9.2% over the last month. Year to date it is down 0.7%, and over longer periods it has returned 23.1% over 1 year, 82.9% over 3 years and 142.8% over 5 years.
• These moves sit against an ongoing flow of news around AbbVie, including product pipeline updates, regulatory decisions and broader sector headlines that can shift how investors think about its long term prospects and risk profile. Even when there is no single major announcement, this steady news stream can influence how comfortable the market feels with the current price.
• On Simply Wall St’s valuation checks AbbVie scores a 2 out of 6. Next up is a closer look at how different valuation methods, and an additional way of interpreting them at the end of the article, can help you put that score into context.

AbbVie scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: AbbVie Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a stock could be worth by projecting future cash flows and then discounting them back to today using a required rate of return.

For AbbVie, the model used is a 2 Stage Free Cash Flow to Equity approach, working off last twelve month free cash flow of about $20.1b. Analyst estimates and Simply Wall St extrapolations in the model point to projected free cash flow of about $35.2b in 2030, with interim projections through 2035 used to build the cash flow path.

On this basis, the DCF model arrives at an estimated intrinsic value of about $439.85 per share. Compared with the recent share price of around $227.73, this output suggests AbbVie is trading at a 48.2% discount to that DCF estimate, indicating a wide gap between the market price and this cash flow based valuation within the assumptions of the model.

Result: UNDERVALUED (based on this DCF model)

Our Discounted Cash Flow (DCF) analysis suggests AbbVie is undervalued by 48.2%. Track this in your watchlist or portfolio, or discover 44 more high quality undervalued stocks.

Approach 2: AbbVie Price vs Earnings

P/E is a common way to look at profitable companies because it links what you pay for the stock directly to the earnings the business is generating today.

In general, higher growth expectations and lower perceived risk can justify a higher P/E, while slower growth or higher uncertainty tend to support a lower, more conservative P/E that investors might see as normal for a stock.

AbbVie is currently trading on a P/E of 111.92x. This is above the Biotechs industry average P/E of 16.47x and above the peer group average of 20.40x. Simply Wall St also calculates a Fair Ratio for AbbVie of 37.34x. This Fair Ratio is a proprietary estimate of what AbbVie’s P/E could be, given its earnings growth profile, industry, profit margins, market cap and risk factors.

Because the Fair Ratio is tailored to AbbVie’s specific characteristics, it can be more informative than a simple comparison with peers or the broad industry, which might have very different growth, risk and profitability profiles.

Comparing the current P/E of 111.92x with the Fair Ratio of 37.34x suggests AbbVie is trading above this Fair Ratio estimate.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your AbbVie Narrative

Earlier the article mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St’s Community page let you attach your own story about AbbVie’s future revenue, earnings and margins to a forecast and fair value, then compare that fair value with the current price, see it update as new news or earnings arrive, and understand why one investor might see AbbVie as closer to the high analyst target of US$328 while another leans toward the lower US$184 view based on the same set of disclosed assumptions and risks.

Do you think there's more to the story for AbbVie? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.